Other Corporate Information – Page 11 – Alligator Bioscience

All IR MAR Regulatory Report

2024-10-29

Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

LUND, SWEDEN and SEATTLE WA / October 29, 2024 / Alligator Bioscience AB (“Alligator”) (ATORX) and Aptevo Therapeutics (“A ...

2024-09-16

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrate ...

2024-09-13

Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024

Lund, Sweden and Seattle, Washington, September 13, 2024 – Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) ...

2024-07-10

Alligator Bioscience Announces Completion of Enrollment in Mitazalimab OPTIMIZE-1 Study

Recruitment completed for the additional cohort with 450 µg/kg of mitazalimab in combination with mFOLFIRINOX as requested by FDA ahea ...

2024-06-26

Regulatory

Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer

Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously repo ...

2024-06-25

Regulatory

Alligator Bioscience announces financing of up to SEK 80 million extending cash runway to Q1 2025

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2024-06-20

Alligator Bioscience to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

Primary endpoint of OPTIMIZE-1 trial was met, with Objective Response Rate (ORR) of 40.4% in 57 evaluable patients Unprecedented Duration of ...

2024-06-03

Alligator Bioscience’s Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology

Publication in world-leading clinical oncology journal validates the quality and potential implications of Phase 2 OPTIMIZE-1 results The st ...

2024-05-23

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-n ...